Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
Browsing: Disease Area > Lung
Initial results from the Phase III CheckMate -227 study have demonstrated that the combination of nivolumab plus ipilimumab can significantly extend PFS in those with previously untreated advanced NSCLC whose tumours have high tumour mutation burden (TMB).
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
What advancements have we witnessed in the field of immunotherapy for lung cancer and what does the future of this field look like? Find out in this article from Lung Cancer Management.
Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed.
Phase III IM power150 study has demonstrated that atezolizumab and bevacizumab plus carboplatin and paclitaxel helped individuals with advanced lung cancer live longer compared to avastin plus carboplatin and paclitaxel.
AstraZeneca’s novel immunotherapy for non-small cell lung cancer has been authorized for use by the FDA.
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
An innovative new platform could transform the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells.